Enzyme replacement therapy for pancreatic insufficiency: Present and future

Clinical and Experimental Gastroenterology

Volumn 4, Issue 1, 2011, Pages 55-73

  Fieker, Aaron ^a   Philpott, Jessica ^a   Armand, Martine ^b  

^a UNIVERSITY OF OKLAHOMA   (United States)

^b INSERM   (France)

Author keywords

Chronic pancreatitis; Cystic fibrosis; Exocrine pancreatic insufficiency; Lipase; Lipids; Pancreatic enzyme replacement therapy

Indexed keywords

ALCOHOL; BICARBONATE; EXINALDA; KIOBRINA; KREON; MERISPASE; PANCREAS ENZYME; PANCREAS EXTRACT; PANCREATIN; PANCREAZE; PANCRELIPASE; RECOMBINANT ENZYME; THERACLEC TOTAL; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; ZENPEP;

CHRONIC PANCREATITIS; CLINICAL FEATURE; CYSTIC FIBROSIS; DOSE RESPONSE; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG SOLUBILITY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ENTERIC COATED TABLET; ENZYME REPLACEMENT; EXCIPIENT COMPATIBILITY; FOLIC ACID DEFICIENCY; HUMAN; LABORATORY TEST; LIPID METABOLISM; LIPIDOSIS; LOW DRUG DOSE; NONHUMAN; OXIDATIVE STRESS; PANCREAS EXOCRINE INSUFFICIENCY; PANCREAS INSUFFICIENCY; PANCREAS SECRETION; REVIEW; STEATORRHEA; STOMACH PH; STOMATITIS; WEIGHT REDUCTION;

EID: 79958139589     PISSN: None     EISSN: 11787023     Source Type: Journal    
DOI: 10.2147/CEG.S17634     Document Type: Review

References (200)

1. Pezzilli R, Morselli Labate AM, Ceciliato R, et al. Quality of life in patients with chronic pancreatitis. Dig Liver Dis. 2005;37(3):181-189.
2. Whitcomb DC, Lehman GA, Vasileva G, et al. Pancrelipase delayedrelease capsules (CREON) for exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery: A double-blind randomized trial. Am J Gastroenterol. 2010;105(10):2276-2286.
3. Ferrone M, Raimondo M, Scolapio JS. Pancreatic enzyme pharmacotherapy. Pharmacotherapy. 2007;27(6):910-920.
4. Yamada T, editor. Textbook of Gastroenterology. Fourth ed: Lippincott Williams & Wilkins; 2003.
5. Bruno MJ, Haverkort EB, Tytgat GN, van Leeuwen DJ. Maldigestion associated with exocrine pancreatic insufficiency: implications of gastrointestinal physiology and properties of enzyme preparations for a cause-related and patient-tailored treatment. Am J Gastroenterol. 1995;90(9):1383-1393.
6. Adler G, Mullenhoff A, Koop I, et al. Stimulation of pancreatic secretion in man by a protease inhibitor (camostate). Eur J Clin Invest. 1988; 18(1):98-104.
7. Braganza JM, Herman K, Hine P, Kay G, Sandle GI. Pancreatic enzymes in human duodenal juice-a comparison of responses in secretin pancreozymin and Lundh Borgstrom tests. Gut. 1978;19(5):358-366.
8. Escourrou J, Frexinos J, Ribet A. Biochemical studies of pancreatic juice collected by duodenal aspiration and endoscopic cannulation of the main pancreatic duct. Am J Dig Dis. 1978;23(2):173-177.
9. Berton A, Sebban-Kreuzer C, Rouvellac S, Lopez C, Crenon I. Individual and combined action of pancreatic lipase and pancreatic lipase-related proteins 1 and 2 on native versus homogenized milk fat globules. Mol Nutr Food Res. 2009;53(12):1592-1602.
10. Borgstrom B. Influence of bile salt, pH, and time on the action of pancreatic lipase. Journal of Lipid Research. 1964;5:522-531.
11. Crenon I, Foglizzo E, Kerfelec B, et al. Pancreatic lipase-related protein type I: a specialized lipase or an inactive enzyme. Protein Eng. 1998; 11(2):135-142
12. De Caro J, Carrière F, Barboni P, Giller T, Verger R, De Caro A. Pancreatic lipase-related protein 1 (PLRP1) is present in the pancreatic juice of several species. Biochim Biophys Acta. 1998;1387(1-2): 331-341.
13. Eydoux C, Aloulou A, De Caro J, et al. Human pancreatic lipase-related protein 2: tissular localization along the digestive tract and quantification in pancreatic juice using a specific ELISA. Biochim Biophys Acta. 2006;1760(10):1497-1504.
14. Hui DY, Howles PN. Carboxyl ester lipase: structure-function relationship and physiological role in lipoprotein metabolism and atherosclerosis. J Lipid Res. 2002;43(12):2017-2030.
15. Jayne S, Kerfelec B, Foglizzo E, Chapus C, Crenon I. High expression in adult horse of PLRP2 displaying a low phospholipase activity. Biochim Biophys Acta. 2002;1594(4):255-265.
16. Lowe ME. The triglyceride lipases of the pancreas. J Lipid Res. 2002;43(12):2007-2016.
17. Reboul E, Berton A, Moussa M, Kreuzer C, Crenon I, Borel P. Pancreatic lipase and pancreatic lipase-related protein 2, but not pancreatic lipase-related protein 1, hydrolyze retinyl palmitate in physiological conditions. Biochim Biophys Acta. 2006;1761(1):4-10.
18. Sias B, Ferrato F, Grandval P, et al. Human pancreatic lipase-related protein 2 is a galactolipase. Biochemistry. 2004;43(31):10138-10148.
19. Thirstrup K, Verger R, Carrière F. Evidence for a pancreatic lipase subfamily with new kinetic properties. Biochemistry. 1994;33(10): 2748-2756.
20. Verheij MH, Westerman J, Sternby B, de Haas GH. The complete primary structure of phospholipase A2 from human pancreas. Biochim Biophys Acta. 1983;747(1-2):93-99.
21. Lowe ME. The structure and function of pancreatic enzymes. In: Johnson LR, Alpers DH, Christensen J, Jacobson ED, Walsh JH, editors. Physiology of the Gastrointestinal Tract. Vol 2. New York: Raven Press; 1994:1531-1542.
22. Lebenthal E, Lee PC. Development of functional responses in human exocrine pancreas. Pediatrics. 1980;66(4):556-560.
23. Zoppi G, Andreotti G, Pajno-Ferrara F, Njai DM, Gaburro D. Exocrine pancreas function in premature and full term neonates. Pediatr Res. 1972;6(12):880-886.
24. Fredrikzon B, Olivecrona T. Decrease of lipase and esterase activities in intestinal contents of newborn infants during test meals. Pediatr Res. 1978;12(5):631-634.
25. Track NS, Creutzfeldt C, Bokermann M. Enzymatic, functional and ultrastructural development of the exocrine pancreas-II. The human pancreas. Comp Biochem Physiol A Comp Physiol. 1975;51(1A): 95-100.
26. Laugier R, Bernard JP, Berthezene P, Dupuy P. Changes in pancreatic exocrine secretion with age: pancreatic exocrine secretion does decrease in the elderly. Digestion. 1991;50(3-4):202-211.
27. Keller J, Layer P. Human pancreatic exocrine response to nutrients in health and disease. Gut. 2005; 54 Suppl 6:vi1-vi28.
28. Armand M. Lipases and lipolysis in the human digestive tract: where do we stand? Curr Opin Clin Nutr Metab Care. 2007;10(2):156-164.
29. Armand M, Borel P, Pasquier B, et al. Physicochemical characteristics of emulsions during fat digestion in human stomach and duodenum. Am J Physiol. 1996;271(1 Pt 1):G172-G183.
30. Armand M, Pasquier B, Andre M, et al. Digestion and absorption of 2 fat emulsions with different droplet sizes in the human digestive tract. Am J Clin Nutr. 1999;70(6):1096-1106.
31. Schwizer W, Asal K, Kreiss C, et al. Role of lipase in the regulation of upper gastrointestinal function in humans. Am J Physiol. 1997; 273(3 Pt 1):G612-G620.
32. Boivin M, Lanspa SJ, Zinsmeister AR, Go VL, DiMagno EP. Are diets associated with different rates of human interdigestive and postprandial pancreatic enzyme secretion? Gastroenterology. 1990;99(6): 1763-1771.
33. Borovicka J, Schwizer W, Mettraux C, et al. Regulation of gastric and pancreatic lipase secretion by CCK and cholinergic mechanisms in humans. Am J Physiol. 1997;273(2 Pt 1):G374-G380.
34. Carrière F, Barrowman JA, Verger R, Laugier R. Secretion and contribution to lipolysis of gastric and pancreatic lipases during a test meal in humans. Gastroenterology. 1993;105(3):876-888.
35. Carrière F, Grandval P, Renou C, et al. Quantitative study of digestive enzyme secretion and gastrointestinal lipolysis in chronic pancreatitis. Clin Gastroenterol Hepatol. 2005;3(1):28-38.
36. Yago MD, Gonzalez MV, Martinez-Victoria E, et al. Pancreatic enzyme secretion in response to test meals differing in the quality of dietary fat (olive and sunflowerseed oils) in human subjects. Br J Nutr. 1997; 78(1):27-39.
37. Layer P, Keller J. Pancreatic enzymes: secretion and luminal nutrient digestion in health and disease. J Clin Gastroenterol. 1999;28(1): 3-10.
38. Carrière F, Renou C, Lopez V, et al. The specific activities of human digestive lipases measured from the in vivo and in vitro lipolysis of testmeals. Gastroenterology. 2000;119(4):949-960.
39. Keller J, Runzi M, Goebell H, Layer P. Duodenal and ileal nutrient deliveries regulate human intestinal motor and pancreatic responses to a meal. Am J Physiol. 1997;272(3 Pt 1):G632-G637.
40. Moreau H, Saunière JF, Gargouri Y, Pieroni G, Verger R, Sarles H. Human gastric lipase: variations induced by gastrointestinal hormones and by pathology. Scand J Gastroenterol. 1988;23(9):1044-1048.
41. Palasciano G, Saunières JF, Laugier R, Sarles H. Pancreatic response to secretin+CCK-PZ in European and North African adults and children. Gut. 1979;20(12):1063-1065.
42. Boehm G, Borte M, Muller H, Moro G, Minoli I. Activities of trypsin and lipase in duodenal aspirates of preterm infants: influence of dietary protein and fat composition. Am J Clin Nutr. 1995;61(3):524-527.
43. Mott C, Sarles H, Tiscornia O, Gullo L. Inhibitory action of alcohol on human exocrine pancreatic secretion. Am J Dig Dis. 1972;17(10): 902-910.
44. Bozkurt T, Adler G, Koop I, Koop H, Turmer W, Arnold R. Plasma CCK levels in patients with pancreatic insufficiency. Dig Dis Sci. 1988; 33(3):276-281.
45. Nouri-Sorkhabi MH, Chapman BE, Kuchel PW, Gruca MA, Gaskin KJ. Parallel secretion of pancreatic phospholipase A(2), phospholipase A(1), lipase, and colipase in children with exocrine pancreatic dysfunction. Pediatr Res. 2000;48(6):735-740.
46. Armand M. Milk fat digestibility. Sciences des Aliments. 2008;28(1-2): 84-98.
47. Mattes RD. Fat taste and lipid metabolism in humans. Physiol Behav. 2005;86(5):691-697.
48. Sarles H, Dani R, Prezelin G, Souville C, Figarella C. Cephalic phase of pancreatic secretion in man. Gut. 1968;9(2):214-221.
49. Solomon T. Control of exocrine pancreas secretion. In: LR J, editor. Physiology of the Gastrointestinal Tract. Vol 2. New York: Raven Press; 1994:1499-1529.
50. Alpers D. Digestion and absorption of carbohydrates and proteins. In: LR J, editor. Physiology of the Gastrointestinal Tract. Vol 2. New York: Raven Press; 1994:1723-1749.
51. Hamosh M. Lingual and gastric lipases. Nutrition. 1990;6(6):421-428.
52. MacGregor I, Parent J, Meyer JH. Gastric emptying of liquid meals and pancreatic and biliary secretion after subtotal gastrectomy or truncal vagotomy and pyloroplasty in man. Gastroenterology. 1977;72(2): 195-205.
53. Mayer EA, Thompson JB, Jehn D, Reedy T, Elashoff J, Meyer JH. Gastric emptying and sieving of solid food and pancreatic and biliary secretion after solid meals in patients with truncal vagotomy and antrectomy. Gastroenterology. 1982;83(1 Pt 2):184-192.
54. Chey WY, Chang T. Neural hormonal regulation of exocrine pancreatic secretion. Pancreatology. 2001;1(4):320-335.
55. Armand M, Borel P, Dubois C, et al. Characterization of emulsions and lipolysis of dietary lipids in the human stomach. Am J Physiol. 1994;266(3 Pt 1):G372-G381.
56. Armand M, Hamosh M, Mehta NR, et al. Effect of human milk or formula on gastric function and fat digestion in the premature infant. Pediatr Res. 1996;40(3):429-437.
57. Bordalo O, Goncalves D, Noronha M, Cristina ML, Salgadinho A, Dreiling DA. Newer concept for the pathogenesis of chronic alcoholic pancreatitis. Am J Gastroenterol. 1977;68(3):278-285.
58. Dahim M, Brockman H. How colipase-fatty acid interactions mediate adsorption of pancreatic lipase to interfaces. Biochemistry. 1998;37(23): 8369-8377.
59. Lindquist S, Hernell O. Lipid digestion and absorption in early life: an update. Curr Opin Clin Nutr Metab Care. 2010;13(3):314-320.
60. Lowe ME, Kaplan MH, Jackson-Grusby L, D'Agostino D, Grusby MJ. Decreased neonatal dietary fat absorption and T cell cytotoxicity in pancreatic lipase-related protein 2-deficient mice. J Biol Chem. 1998; 273(47):31215-31221.
61. Tso P. Intestinal lipid absorption. In: LR J, editor. Physiology of the Gastrointestinal Tract. Vol 2. New York: Raven Press; 1994: 1867-1908.
62. Hernell O, Staggers JE, Carey MC. Physical-chemical behavior of dietary and biliary lipids during intestinal digestion and absorption. 2. Phase analysis and aggregation states of luminal lipids during duodenal fat digestion in healthy adult human beings. Biochemistry. 1990;29(8):2041-2056.
63. Mu H, Hoy CE. The digestion of dietary triacylglycerols. Prog Lipid Res. 2004;43(2):105-133.
64. Layer P, Yamamoto H, Kalthoff L, Clain JE, Bakken LJ, DiMagno EP. The different courses of early- and late-onset idiopathic and alcoholic chronic pancreatitis. Gastroenterology. 1994;107(5):1481-1487.
65. Roberts IM, Poturich C, Wald A. Utility of fecal fat concentrations as screening test in pancreatic insufficiency. Dig Dis Sci. 1986;31(10): 1021-1024.
66. Fine KD, Schiller LR. AGA technical review on the evaluation and management of chronic diarrhea. Gastroenterology. 1999;116(6): 1464-1486.
67. Ewald N, Raspe A, Kaufmann C, Bretzel RG, Kloer HU, Hardt PD. Determinants of exocrine pancreatic function as measured by fecal elastase-1 concentrations (FEC) in patients with diabetes mellitus. Eur J Med Res. 2009;14(3):118-122.
68. Naruse S, Ishiguro H, Ko SB, et al. Fecal pancreatic elastase: a reproducible marker for severe exocrine pancreatic insufficiency. J Gastroenterol. 2006;41(9):901-908.
69. Hahn JU, Kerner W, Maisonneuve P, Lowenfels AB, Lankisch PG. Low fecal elastase 1 levels do not indicate exocrine pancreatic insufficiency in type-1 diabetes mellitus. Pancreas. 2008;36(3):274-278.
70. Lankisch PG, Schmidt I, Konig H, et al. Faecal elastase 1: not helpful in diagnosing chronic pancreatitis associated with mild to moderate exocrine pancreatic insufficiency. Gut. 1998;42(4):551-554.
71. Layer P, Keller J. Lipase supplementation therapy: standards, alternatives, and perspectives. Pancreas. 2003;26(1):1-7.
72. Dominguez-Munoz JE. Pancreatic enzyme therapy for pancreatic exocrine insufficiency. Curr Gastroenterol Rep. 2007;9(2):116-122.
73. Montalto G, Soresi M, Carroccio A, et al. Lipoproteins and chronic pancreatitis. Pancreas. 1994;9(1):137-138.
74. Pezzilli R. Chronic pancreatitis: maldigestion, intestinal ecology and intestinal inflammation. World J Gastroenterol. 2009;15(14): 1673-1676.
75. Gielkens HA, Eddes EH, Vecht J, van Oostayen JA, Lamers CB, Masclee AA. Gallbladder motility and cholecystokinin secretion in chronic pancreatitis: relationship with exocrine pancreatic function. J Hepatol. 1997;27(2):306-312.
76. Krishnamurty DM, Rabiee A, Jagannath SB, Andersen DK. Delayed release pancrelipase for treatment of pancreatic exocrine insufficiency associated with chronic pancreatitis. Ther Clin Risk Manag. 2009;5(3): 507-520.
77. Long WB, Weiss JB. Rapid gastric emptying of fatty meals in pancreatic insufficiency. Gastroenterology. 1974;67(5):920-925.
78. Mizushima T, Ochi K, Ichimura M, Kiura K, Harada H, Koide N. Pancreatic enzyme supplement improves dysmotility in chronic pancreatitis patients. J Gastroenterol Hepatol. 2004;19(9): 1005-1009.
79. Nustede R, Kohler H, Folsch UR, Schafmayer A. Plasma concentrations of neurotensin and CCK in patients with chronic pancreatitis with and without enzyme substitution. Pancreas. 1991;6(3):260-265.
80. Vu MK, Vecht J, Eddes EH, Biemond I, Lamers CB, Masclee AA. Antroduodenal motility in chronic pancreatitis: are abnormalities related to exocrine insufficiency? Am J Physiol Gastrointest Liver Physiol. 2000;278(3):G458-G466.
81. Czako L, Hegyi P, Rakonczay Z Jr, Wittmann T, Otsuki M. Interactions between the endocrine and exocrine pancreas and their clinical relevance. Pancreatology. 2009;9(4):351-359.
82. Bragelmann R, Armbrecht U, Rosemeyer D, Schneider B, Zilly W, Stockbrugger RW. The effect of pancreatic enzyme supplementation in patients with steatorrhoea after total gastrectomy. Eur J Gastroenterol Hepatol. 1999;11(3):231-237.
83. Creutzfeldt W, Gleichmann D, Otto J, Stockmann F, Maisonneuve P, Lankisch PG. Follow-up of exocrine pancreatic function in type-1 diabetes mellitus. Digestion. 2005;72(2-3):71-75.
84. Lankisch PG, Manthey G, Otto J, et al. Exocrine pancreatic function in insulin-dependent diabetes mellitus. Digestion. 1982;25(3): 211-216.
85. Hardt PD, Hauenschild A, Nalop J, et al. High prevalence of exocrine pancreatic insufficiency in diabetes mellitus. A multicenter study screening fecal elastase 1 concentrations in 1,021 diabetic patients. Pancreatology. 2003;3(5):395-402.
86. Sarles H. Etiopathogenesis and definition of chronic pancreatitis. Dig Dis Sci. 1986;31(9 Suppl):91S-107S.
87. Sarles H, Bernard JP, Gullo L. Pathogenesis of chronic pancreatitis. Gut. 1990;31(6):629-632.
88. Comfort MW, Gambrill EE, Baggenstoss AH. Chronic relapsing pancreatitis. A study of twenty-nine cases without associated disease of the biliary or gastro-intestinal tract. Gastroenterology. 1968; 54(4): Suppl: 760-765.
89. Kloppel G, Maillet B. Chronic pancreatitis: evolution of the disease. Hepatogastroenterology. 1991;38(5):408-412.
90. Braganza JM. Pancreatic disease: a casualty of hepatic "detoxification"? Lancet. 1983;2(8357):1000-1003.
91. Ekstrom G, Ingelman-Sundberg M. Rat liver microsomal NADPHsupported oxidase activity and lipid peroxidation dependent on ethanol-inducible cytochrome P-450 (P-450IIE1). Biochem Pharmacol. 1989;38(8):1313-1319.
92. Marshall WJ, McLean AE. A requirement for dietary lipids for induction of cytochrome P-450 by phenobarbitone in rat liver microsomal fraction. Biochem J. 1971;122(4):569-573.
93. Cavallini G. Is chronic pancreatitis a primary disease of the pancreatic ducts? A new pathogenetic hypothesis. Ital J Gastroenterol. 1993; 25(7):391-396.
94. DiMagno MJ, DiMagno EP. Chronic pancreatitis. Curr Opin Gastroenterol. 2005;21(5):544-554.
95. Stevens T, Conwell DL, Zuccaro G. Pathogenesis of chronic pancreatitis: an evidence-based review of past theories and recent developments. Am J Gastroenterol. 2004;99(11):2256-2270.
96. Wilschanski M, Durie PR. Patterns of GI disease in adulthood associated with mutations in the CFTR gene. Gut. 2007;56(8):1153-1163.
97. Armand M, Hamosh M, Philpott JR, et al. Gastric function in children with cystic fibrosis: effect of diet on gastric lipase levels and fat digestion. Pediatr Res. 2004;55(3):457-465.
98. Andersen JR, Bendtsen F, Ovesen L, Pedersen NT, Rune SJ, Tage-Jensen U. Pancreatic insufficiency. Duodenal and jejunal pH, bile acid activity, and micellar lipid solubilization. Int J Pancreatol. 1990;6(4):263-270.
99. Dutta SK, Russell RM, Iber FL. Influence of exocrine pancreatic insufficiency on the intraluminal pH of the proximal small intestine. Dig Dis Sci. 1979;24(7):529-534.
100. Dutta SK, Russell RM, Iber FL. Impaired acid neutralization in the duodenum in pancreatic insufficiency. Dig Dis Sci. 1979;24(10): 775-780.
101. Bruno MJ, Rauws EA, Hoek FJ, Tytgat GN. Comparative effects of adjuvant cimetidine and omeprazole during pancreatic enzyme replacement therapy. Dig Dis Sci. 1994;39(5):988-992.
102. Chauhan S, Forsmark CE. Pain management in chronic pancreatitis: A treatment algorithm. Best Pract Res Clin Gastroenterol. 2010;24(3): 323-335.
103. Massicotte LP, Baille WE, Mateescu MA. Carboxylated high amylase starch as pharmaceutical excipients. Structural insights and formulation of pancreatic enzymes. Int J Pharm. 2008;356(1-2): 212-223.
104. Naikwade SR, Meshram RN, Bajaj AN. Preparation and in vivo efficacy study of pancreatin microparticles as an enzyme replacement therapy for pancreatitis. Drug Dev Ind Pharm. 2009;35(4): 417-432.
105. Robinson PJ, Smith AL, Sly PD. Duodenal pH in cystic fibrosis and its relationship to fat malabsorption. Dig Dis Sci. 1990;35(10): 1299-1304.
106. Aloulou A, Puccinelli D, Sarles J, Laugier R, Leblond Y, Carrière F. In vitro comparative study of three pancreatic enzyme preparations: dissolution profiles, active enzyme release and acid stability. Aliment Pharmacol Ther. 2008;27(3):283-292.
107. Kraisinger M, Hochhaus G, Stecenko A, Bowser E, Hendeles L. Clinical pharmacology of pancreatic enzymes in patients with cystic fibrosis and in vitro performance of microencapsulated formulations. J Clin Pharmacol. 1994;34(2):158-166.
108. Case CL, Henniges F, Barkin JS. Enzyme content and acid stability of enteric-coated pancreatic enzyme products in vitro. Pancreas. 2005;30(2):180-183.
109. Meyer JH, Elashoff J, Porter-Fink V, Dressman J, Amidon GL. Human postprandial gastric emptying of 1-3-millimeter spheres. Gastroenterology. 1988;94(6):1315-1325.
110. Meyer JH, Lake R. Mismatch of duodenal deliveries of dietary fat and pancreatin from enterically coated microspheres. Pancreas. 1997; 15(3):226-235.
111. Hendeles L, Dorf A, Stecenko A, Weinberger M. Treatment failure after substitution of generic pancrelipase capsules. Correlation with in vitro lipase activity. JAMA. 1990;263(18):2459-2461.
112. Traynor K. FDA approves third pancrelipase product: Unapproved products illegal to market after April 28. Am J Health Syst Pharm. 2010;67(10):776.
113. Graff GR, Maguiness K, McNamara J, et al. Efficacy and tolerability of a new formulation of pancrelipase delayed-release capsules in children aged 7 to 11 years with exocrine pancreatic insufficiency and cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled,two-period crossover, superiority study. Clin Ther. 2010;32(1): 89-103.
114. Graff GR, McNamara J, Royall J, Caras S, Forssmann K. Safety and tolerability of a new formulation of pancrelipase delayed-release capsules (CREON) in children under seven years of age with exocrine pancreatic insufficiency due to cystic fibrosis: an open-label, multicentre, single-treatment-arm study. Clin Drug Investig. 2010; 30(6):351-364.
115. Trapnell BC, Maguiness K, Graff GR, Boyd D, Beckmann K, Caras S. Efficacy and safety of Creon 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis. J Cyst Fibros. 2009;8(6): 370-377.
116. Wooldridge JL, Heubi JE, Amaro-Galvez R, et al. EUR-1008 pancreatic enzyme replacement is safe and effective in patients with cystic fibrosis and pancreatic insufficiency. J Cyst Fibros. 2009;8(6): 405-417.
117. Lohr JM, Hummel FM, Pirilis KT, Steinkamp G, Korner A, Henniges F. Properties of different pancreatin preparations used in pancreatic exocrine insufficiency. Eur J Gastroenterol Hepatol. 2009;21(9): 1024-1031.
118. Walters MP, Littlewood JM. Pancreatin preparations used in the treatment of cystic fibrosis - lipase content and in vitro release. Aliment Pharmacol Ther. 1996;10(3):433-440.
119. Kolbel C, Layer P, Hotz J, Goebell H. Effect of an acid protected, micro-encapsulated pancreatin preparation on pancreatogenic steatorrhea. Med Klin (Munich). 1986;81(3):85-86.
120. Dominguez-Munoz JE, Iglesias-Garcia J, Iglesias-Rey M, Figueiras A, Vilarino-Insua M. Effect of the administration schedule on the therapeutic efficacy of oral pancreatic enzyme supplements in patients withexocrine pancreatic insufficiency: a randomized, three-way crossover study. Aliment Pharmacol Ther. 2005;21(8): 993-1000.
121. O'Keefe SJ, Cariem AK, Levy M. The exacerbation of pancreatic endocrine dysfunction by potent pancreatic exocrine supplements in patients with chronic pancreatitis. J Clin Gastroenterol. 2001;32(4): 319-323.
122. Safdi M, Bekal PK, Martin S, Saeed ZA, Burton F, Toskes PP. The effects of oral pancreatic enzymes (Creon 10 capsule) on steatorrhea: a multicenter, placebo-controlled, parallel group trial in subjects with chronic pancreatitis. Pancreas. 2006;33(2):156-162.
123. Stern RC, Eisenberg JD, Wagener JS, et al. A comparison of the efficacy and tolerance of pancrelipase and placebo in the treatment of steatorrhea in cystic fibrosis patients with clinical exocrine pancreatic insufficiency. Am J Gastroenterol. 2000;95(8):1932-1938.
124. Baker SS. Delayed release pancrelipase for the treatment of pancreatic exocrine insufficiency associated with cystic fibrosis. Ther Clin Risk Manag. 2008;4(5):1079-1084.
125. Baker SS, Borowitz D, Duffy L, Fitzpatrick L, Gyamfi J, Baker RD. Pancreatic enzyme therapy and clinical outcomes in patients with cystic fibrosis. J Pediatr. 2005;146(2):189-193.
126. Dominguez-Munoz JE, Iglesias-Garcia J. Oral pancreatic enzyme substitution therapy in chronic pancreatitis: is clinical response an appropriate marker for evaluation of therapeutic efficacy? JOP. 2010;11(2):158-162.
127. Lembcke B, Braden B, Caspary WF. Exocrine pancreatic insufficiency: accuracy and clinical value of the uniformLy labelled 13C-Hiolein breath test. Gut. 1996;39(5):668-674.
128. Ritz MA, Fraser RJ, Di Matteo AC, et al. Evaluation of the 13C-triolein breath test for fat malabsorption in adult patients with cystic fibrosis. J Gastroenterol Hepatol. 2004;19(4):448-453.
129. Ventrucci M, Cipolla A, Ubalducci GM, Roda A, Roda E. 13C labeled cholesteryl octanoate breath test for assessing pancreatic exocrine insufficiency. Gut. 1998;42(1):81-87.
130. Vantrappen GR, Rutgeerts PJ, Ghoos YF, Hiele MI. Mixed triglyceride breath test: a noninvasive test of pancreatic lipase activity in the duodenum. Gastroenterology. 1989;96(4):1126-1134.
131. Nakamura H, Morifuji M, Murakami Y, et al. Usefulness of a 13C-labeled mixed triglyceride breath test for assessing pancreatic exocrine function after pancreatic surgery. Surgery. 2009;145(2): 168-175.
132. Dominguez-Munoz JE, Iglesias-Garcia J, Vilarino-Insua M, Iglesias-Rey M. 13C-mixed triglyceride breath test to assess oral enzyme substitution therapy in patients with chronic pancreatitis. Clin Gastroenterol Hepatol. 2007;5(4):484-488.
133. Colombo C, Fredella C, Russo MC, et al. Efficacy and tolerability of Creon for Children in infants and toddlers with pancreatic exocrine insufficiency caused by cystic fibrosis: an open-label, single-arm, multicenter study. Pancreas. 2009;38(6):693-699.
134. Shafiq N, Rana S, Bhasin D, et al. Pancreatic enzymes for chronic pancreatitis. Cochrane Database Syst Rev. 2009;4: CD006302.
135. Stapleton FB, Kennedy J, Nousia-Arvanitakis S, Linshaw MA. Hyperuricosuria due to high-dose pancreatic extract therapy in cystic fibrosis. N Engl J Med. 1976;295(5):246-248.
136. Hauser R, Duty S, Godfrey-Bailey L, Calafat AM. Medications as a source of human exposure to phthalates. Environ Health Perspect. 2004;112(6):751-753.
137. FitzSimmons SC, Burkhart GA, Borowitz D, et al. High-dose pancreatic- enzyme supplements and fibrosing colonopathy in children with cystic fibrosis. N Engl J Med. 1997;336(18):1283-1289.
138. Bansi DS, Price A, Russell C, Sarner M. Fibrosing colonopathy in an adult owing to over use of pancreatic enzyme supplements. Gut. 2000;46(2):283-285.
139. Van Velzen D, Ball LM, Dezfulian AR, Southgate A, Howard CV. Comparative and experimental pathology of fibrosing colonopathy. Postgrad Med J. 1996;72 Suppl 2:S39-S48; discussion S49-S51.
140. Smyth RL, Ashby D, O'Hea U, et al. Fibrosing colonopathy in cystic fibrosis: results of a case-control study. Lancet. 1995;346(8985): 1247-1251.
141. Prescott P, Bakowski MT. Pathogenesis of fibrosing colonopathy: the role of methacrylic acid copolymer. Pharmacoepidemiol Drug Saf. 1999;8(6):377-384.
142. Prescott P. Pancreatic enzymes and fibrosing colonopathy. Lancet. 1999;354(9174):250; author reply 251.
143. Gaia E, Sambatoro A, De Giuli P, Angeli A. Adult f ibrosing colonopathy associated with mesalazine treatment. Am J Gastroenterol. 2001;96(8):2508-2509.
144. Regan PT, Malagelada JR, Dimagno EP, Go VL. Rationale for the use of cimetidine in pancreatic insufficiency. Mayo Clin Proc. 1978;53(2): 79-83.
145. Durie PR, Bell L, Linton W, Corey ML, Forstner GG. Effect of cimetidine and sodium bicarbonate on pancreatic replacement therapy in cystic fibrosis. Gut. 1980;21(9):778-786.
146. Carroccio A, Pardo F, Montalto G, et al. Use of famotidine in severe exocrine pancreatic insufficiency with persistent maldigestion on enzymatic replacement therapy. A long-term study in cystic fibrosis. Dig Dis Sci. 1992;37(9):1441-1446.
147. Vecht J, Symersky T, Lamers CB, Masclee AA. Efficacy of lower than standard doses of pancreatic enzyme supplementation therapy during acid inhibition in patients with pancreatic exocrine insufficiency. J Clin Gastroenterol. 2006;40(8):721-725.
148. Vukovic M, Jojic N. Effect of enteric coated sodium bicarbonate, enzymes and bile combination on the absorption of fat in chronic pancreatitis. Ann Gastroenterol. 2000;13(2):113-117.
149. Brady MS, Garson JL, Krug SK, et al. An enteric-coated high-buffered pancrelipase reduces steatorrhea in patients with cystic fibrosis: a prospective, randomized study. J Am Diet Assoc. 2006;106(8): 1181-1186.
150. Kalnins D, Ellis L, Corey M, et al. Enteric-coated pancreatic enzyme with bicarbonate is equal to standard enteric-coated enzyme in treating malabsorption in cystic fibrosis. J Pediatr Gastroenterol Nutr. 2006; 42(3):256-261.
151. Barraclough M, Taylor CJ. Twenty-four hour ambulatory gastric and duodenal pH profiles in cystic fibrosis: effect of duodenal hyperacidity on pancreatic enzyme function and fat absorption. J Pediatr Gastroenterol Nutr. 1996;23(1):45-50.
152. Aloulou A, Carrière F. Gastric lipase: an extremophilic interfacial enzyme with medical applications. Cell Mol Life Sci. 2008;65(6): 851-854.
153. Gruber V, Berna P, Arnaud T, et al. Large-scale production of a therapeutic protein in transgenic tobacco plants: effect of subcellular targeting on quality of a recombinant dog gastric lipase. Mol Breed. 2001;7:329-340.
154. Bernback S, Blackberg L. Human gastric lipase. The N-terminal tetrapeptide is essential for lipid binding and lipase activity. Eur J Biochem. 1989;182(3):495-499.
155. Armand M, Hamosh M, DiPalma JS, et al. Dietary fat modulates gastric lipase activity in healthy humans. Am J Clin Nutr. 1995;62(1): 74-80.
156. Pafumi Y, Lairon D, de la Porte PL, et al. Mechanisms of inhibition of triacylglycerol hydrolysis by human gastric lipase. J Biol Chem. 2002;277(31):28070-28079.
157. Lenoir GR, Knoop C, Durieu I, et al. Efficacy and safety of a recombinant gastric lipase produced in corn for the treatment of fat malabsorption in cystic fibrosis. [abstract] Pediatr Pulmonol. 2006;Suppl 29:293.
158. Lenoir G, Dubray C, Chiron R, et al. Recombinant gastric lipase (RGL) for the treatment of fat malabsorption. [abstract] Pediatr Pulmonol. 2008;Suppl 31:306.
159. Moreau J, Bouisson M, Saint-Marc-Girardin MF, Pignal F, Bommelaer G, Ribet A. Comparison of fungal lipase and pancreatic lipase in exocrine pancreatic insufficiency in man. Study of their in vitro properties and intraduodenal bioavailability. Gastroenterol Clin Biol. 1988;12(11): 787-792.
160. Griffin SM, Alderson D, Farndon JR. Acid resistant lipase as replacement therapy in chronic pancreatic exocrine insufficiency: a study in dogs. Gut. 1989;30(7):1012-1015.
161. Zentler-Munro PL, Assoufi BA, Balasubramanian K, et al. Therapeutic potential and clinical efficacy of acid-resistant fungal lipase in the treatment of pancreatic steatorrhoea due to cystic fibrosis. Pancreas. 1992;7(3):311-319.
162. Aloulou A, Puccinelli D, De Caro A, Leblond Y, Carrière F. A comparative study on two fungal lipases from Thermomyces lanuginosus and Yarrowia lipolytica shows the combined effects of detergents and pH on lipase absorption and activity. Biochim Biophys Acta. 2007;1771(12):1446-1456.
163. Turki S, Ayed A, Chalghoumi N, Weekers F, Thonart P, Kallel H. An enhanced process for the production of a highly purif ied extracellular lipase in the non-conventional yeast Yarrowia lipolytica. Appl Biochem Biotechnol. 2010;160(5):1371-1385.
164. Borowitz D, Goss CH, Limauro S, et al. Study of a novel pancreatic enzyme replacement therapy in pancreatic insufficient subjects with cystic fibrosis. J Pediatr. 2006;149(5):658-662.
165. Borowitz D, Goss CH, Stevens C, et al. Safety and preliminary clinical activity of a novel pancreatic enzyme preparation in pancreatic insufficient cystic fibrosis patients. Pancreas. 2006;32(3): 258-263.
166. Borowitz D, Falzone RP, Fratazzi C. A phase 3 study of the efficacy and safety of ALTU-135 (Trizytek) for treatment of pancreatic insufficiency in CF. [abstract] Pediatr Pulmonol. 2008; Suppl 31:423.
167. Aldridge S. Lilly snaps up Alnara. Nat Biotechnol. 2010;28:882.
168. Hasan F, Shah AA, Hameed A. Methods for detection and characterization of lipases: A comprehensive review. Biotechnol Adv. 2009;27(6):782-798.
169. Mala JG, Takeuchi S. Understanding structural features of microbial lipases-an overview. Anal Chem Insights. 2008;3:9-19.
170. Tursi JM, Phair PG, Barnes GL. Plant sources of acid stable lipases: potential therapy for cystic fibrosis. J Paediatr Child Health. 1994; 30(6):539-543.
171. Cambon E, Rodriguez JA, Pina M, et al. Characterization of typo-, regio-, and stereo-selectivities of babaco latex lipase in aqueous and organic media. Biotechnol Lett. 2008;30(4):769-774.
172. Moulin A, Teissere M, Bernard C, Pieroni G. Lipases of the euphorbiaceae family: purification of a lipase from Euphorbia characias latex and structure-function relationships with the B chain of ricin. Proc Natl Acad Sci U S A. 1994;91(24):11328-11332.
173. Quian Z, Fields CJ, Yu Y, Lutz S. Recent progress in engineering alpha/beta hydrolase-fold family members. Biotechnol J. 2007;2(2): 192-200.
174. Aloulou A, Rodriguez JA, Fernandez S, et al. Exploring the specific features of interfacial enzymology based on lipase studies. Biochim Biophys Acta. 2006;1761(9):995-1013.
175. Merten OW, Mattanovich D, Lang C, et al. editors. Recombinant Protein Production with Prokaryotic and Eukaryotic Cells. A Comparative View on Host Physiology. The Netherlands: Kluwer Academic Publishers; 2001.
176. Vitale A, Pedrazzini E. Recombinant pharmaceuticals from plants: the plant endomembrane system as bioreactor. Mol Interv. 2005; 5(4):216-225.
177. Strandvik B, Hansson L, Hernell O, et al. Recombinant human bile salt-stimulates lipase improves lipid uptake and reduces the pancreatic enzyme supplementation in patients with cystic fibrosis. [abstract] Pediatr Pulmonol. 2004;Suppl 27:333.
178. Neves-Petersen MT, Petersen EI, Fojan P, Noronha M, Madsen RG, Petersen SB. Engineering the pH-optimum of a triglyceride lipase: from predictions based on electrostatic computations to experimental results. J Biotechnol. 2001;87(3):225-254.
179. Colin DY, Deprez-Beauclair P, Silva N, Infantes L, Kerfelec B. Modification of pancreatic lipase properties by directed molecular evolution. Protein Eng Des Sel. 2010;23(5):365-373.
180. Drouault S, Corthier G, Ehrlich SD, Renault P. Expression of the Staphylococcus hyicus lipase in Lactococcus lactis. Appl Environ Microbiol. 2000;66(2):588-598.
181. Drouault S, Juste C, Marteau P, Renault P, Corthier G. Oral treatment with Lactococcus lactis expressing Staphylococcus hyicus lipase enhances lipid digestion in pigs with induced pancreatic insufficiency. Appl Environ Microbiol. 2002;68(6):3166-3168.
182. Kuhel DG, Zheng S, Tso P, Hui DY. Adenovirus-mediated human pancreatic lipase gene transfer to rat bile: gene therapy of fat malabsorption. Am J Physiol Gastrointest Liver Physiol. 2000;279(5): G1031-G1036.
183. Brockman H. General Features of Lipolysis: Reaction Scheme, Interfacial Structure and Experimental Approaches: Elsevier; 1984.
184. Favé G, Coste TC, Armand M. Physicochemical properties of lipids: new strategies to manage fatty acid bioavailability. Cell Mol Biol (Noisy-le-grand). 2004;50(7):815-831.
185. Golding M, Wooster TJ. The influence of emulsion structure and stability on lipid digestion. Curr Opin Colloid Interface Sci. 2010;15: 90-101.
186. Singh H, Ye A, Horne D. Structuring food emulsions in the gastrointestinal tract to modify lipid digestion. Prog Lipid Res. 2009; 48(2):92-100.
187. Tsuzuki W, Ue A, Nagao A, Endo M, Abe M. Inhibitory effect of lysophosatidylcholine on pancreatic lipase-mediated hydrolysis in lipid emulsion. Biochim Biophys Acta. 2004;1684(1-3):1-7.
188. Armand M, Pieroni G, Inventors; Innovation Santé des Lipides (I.S.L.)/I.N.S.E.R.M., assignee. Foodstuff composition to improve digestibility of Foodstuff lipids. French patent WO 2009/037398, International Application No.: PCT/FR2008/001062.
189. Favé G, Lévêque C, Peyrot J, Pieroni G, Coste TC, Armand M. Modulation of gastric lipolysis by the phospholipid specie: link to specific lipase-phospholipid interaction at the lipid/water interface? [abstract] FASEB Journal. 2007;21:A1010-a.
190. Mun S, Decker EA, McClements DJ. Influence of emulsifier type on in vitro digestibility of lipid droplets by pancreatic lipase. Food Res Intern. 2007;40(6):770-781.
191. Hubbard VS, McKenna MC. Absorption of safflower oil and structured lipid preparations in patients with cystic fibrosis. Lipids. 1987;22(6): 424-428.
192. Lucas A, Quinlan P, Abrams S, Ryan S, Meah S, Lucas PJ. Randomised controlled trial of a synthetic triglyceride milk formula for preterm infants. Arch Dis Child Fetal Neonatal Ed. 1997;77(3): F178-F184.
193. Mu H, Porsgaard T. The metabolism of structured triacylglycerols. Prog Lipid Res. 2005;44(6):430-448.
194. Tso P, Lee T, Demichele SJ. Lymphatic absorption of structured triglycerides vs physical mix in a rat model of fat malabsorption. Am J Physiol. 1999;277(2 Pt 1):G333-G340.
195. Jandacek RJ, Whiteside JA, Holcombe BN, Volpenhein RA, Taulbee JD. The rapid hydrolysis and efficient absorption of triglycerides with octanoic acid in the 1 and 3 positions and long-chain fatty acid in the 2 position. Am J Clin Nutr. 1987;45(5):940-945.
196. Kimura M, Shizuki M, Miyoshi K, et al. Relationship between the molecular structures and emulsification properties of edible oils. Biosci Biotechnol Biochem. 1994;58:1258-1261.
197. Bracco U. Effect of triglyceride structure on fat absorption. Am J Clin Nutr. 1994;60(6 Suppl):1002S-1009S.
198. Innis SM, Dyer RA, Lien EL. Formula containing randomized fats with palmitic acid (16:0) in the 2-position increases 16:0 in the 2-position of plasma and chylomicron triglycerides in formula-fed piglets to levels approaching those of piglets fed sow's milk. J Nutr. 1997;127(7):1362-1370.
199. Kritchevsky D. Fatty acids, triglyceride structure, and lipid metabolism. J Nutr Biochem. 1995;127(7):1362-1370.
200. Christensen MS, Hoy CE, Becker CC, Redgrave TG. Intestinal absorption and lymphatic transport of eicosapentaenoic (EPA), docosahexaenoic (DHA), and decanoic acids: dependence on intramolecular triacylglycerol structure. Am J Clin Nutr. 1995;61(1): 56-61.